Journal
VIRUSES-BASEL
Volume 7, Issue 11, Pages 6080-6088Publisher
MDPI AG
DOI: 10.3390/v7112929
Keywords
BLV; HTLV-1; Tax; microRNA; vaccine; HDAC
Categories
Funding
- Fonds National de la Recherche Scientifique (FNRS)
- Televie
- Interuniversity Attraction Poles (IAP) Program Virus-host interplay at the early phases of infection BELVIR
- Belgian Science Policy Office
- Belgian Foundation against Cancer (FBC)
- Sixth Research Framework Programme of the European Union (project The role of infections in cancer INCA) [LSHC-CT-2005-018704]
- Neoangio excellence program
- Partenariat Public Prive, PPP INCA, of the Direction generale des Technologies, de la Recherche et de l'Energie of the Walloon government [DG06]
- Action de Recherche Concertee Glyvir (ARC) of the Communaute francaise de Belgique
- Centre anticancereux pres ULg (CAC)
- Subside Federal de Soutien a la Recherche Synbiofor and Agricultureislife projects of Gembloux Agrobiotech (GxABT)
- ULg Fonds Speciaux pour la Recherche
- Plan Cancer of the Service Public Federal
- Instituto Nacional de Tecnologia Agropecuaria (INTA)
- Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)
Ask authors/readers for more resources
Different animal models have been proposed to investigate the mechanisms of Human T-lymphotropic Virus (HTLV)-induced pathogenesis: rats, transgenic and NOD-SCID/cnull (NOG) mice, rabbits, squirrel monkeys, baboons and macaques. These systems indeed provide useful information but have intrinsic limitations such as lack of disease relevance, species specificity or inadequate immune response. Another strategy based on a comparative virology approach is to characterize a related pathogen and to speculate on possible shared mechanisms. In this perspective, bovine leukemia virus (BLV), another member of the deltaretrovirus genus, is evolutionary related to HTLV-1. BLV induces lymphoproliferative disorders in ruminants providing useful information on the mechanisms of viral persistence, genetic determinants of pathogenesis and potential novel therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available